Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser

NCT01578421 is registered in ClinicalTrials.gov with Kantonsspital Aarau as lead sponsor.

NCT NCT01578421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01578421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser
Lead sponsor
Kantonsspital Aarau
Phase
Not applicable
Overall status
Completed
Start date
February 29, 2012
Completion date
December 31, 2012
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal failure chronic requiring hemodialysis